National and Kapodistrian University of Athens
Φαρμακογονιδιωματική αξιολόγηση της δράσης της ανασυσταμένης HDL με απολιποπρωτεΐνη Ε3 κατά της αθηροσκλήρωσης
Abstract
dc:descriptionAtherosclerotic coronary artery disease (ASCAD) is the leading cause of mortality worldwide, despite the multitude of available lipid-lowering drugs, raising the need for novel and more effective therapeutic approaches. Increasing plasma HDL (High Density Lipoprotein) cholesterol (HDL-C) levels alone is not sufficient for achieving atheroprotection, but rather HDL functionality must be ensured. Towards this direction and given the numerous atheroprotective properties of apolipoprotein E3 (apoE3), reconstituted HDL containing human apoE3 and phospholipids (rHDL-apoE3) represents a promising yet largely unexplored therapeutic agent. The current PhD thesis focused on the evaluation of the atheroprotective potential of rHDL-apoE3 at the cellular, molecular and functional level. Firstly, cutting-edge pharmacogenomic analysis evaluating whole genome expression of primary human aortic endothelial cells (ECs) (HAEC) treated with rHDL-apoE3 or PBS (control) was performed using microarrays followed by high-throughput quantitative RT-PCR. Multilevel bioinformatical analysis revealed that rHDL-apoE3 induced significant expression changes in 198 genes of HAEC mainly associated with functions that are involved in vascular endothelial repair following injury and regulation of atherosclerosis progression. Following extensive literature mining it emerged that rHDL-apoE3 induced expression changes in numerous signaling pathways involved in proliferation (37 genes), differentiation (25), apoptosis (26) and survival (14) of ECs. EC migration was the most highly and significantly changed function, with 44 significantly changed genes. In-depth investigation of the role of these transcripts and their corresponding proteins revealed their central role in the main EC migration-related signaling pathways: 1) MEK1/2/ERK1/2, 2) PI3K/AKT/eNOS-MMP2/9, 3) RHO-GTPases, and 4) integrin. The rHDL-apoE3 induced overexpression of four key genes of these pathways - PIK3CG, EFNB2, ID1 and FLT1 - was also validated at the protein level in primary human coronary artery ECs (HCAEC) and the human EC line EA.hy926. rHDL-apoE3 also increased the phosphorylation of main downstream effectors of these pathways - ERK1/2, AKT, p38 MAPK and eNOS - in these cells. In addition, rHDL-apoE3 increased migration of HCAEC and EA.hy926 cells, as assessed by “wound healing” and “transwell” migration assays. MEK1/2 inhibition using the chemical inhibitor PD98059 completely prevented rHDL-apoE3-induced HCAEC migration and inhibited rHDL-apoE3-mediated ERK1/2 phosphorylation in these cells. Similarly, PI3K inhibition using the chemical inhibitor LY294002 markedly attenuated induction of HCAEC migration by rHDL-apoE3 and inhibited rHDL-apoE3-mediated phosphorylation of AKT and p38 MAPK in these cells. Chemical inhibition of PI3K did not affect eNOS phosphorylation by rHDL-apoE3 in HCAEC, suggesting that a PI3K-independent mechanism is involved. siRNA-mediated gene silencing of the transcription factor ID1 markedly decreased induction of EA.hy926 cell migration by rHDL-apoE3 through inhibition of ERK1/2 and AKT phosphorylation. The overall findings of this PhD thesis indicate that rHDL-apoE3 affects a number of molecular mechanisms associated with atheroprotection. By focusing specifically on endothelial cell migration, it emerged that the MEK1/2/ERK1/2, PI3K/AKT/eNOS-MMP2/9 and RHO-GTPases migration pathways, which are activated through ID1 overexpression, play a central role in this effect. Importantly, we demonstrated that these are the main mechanisms through which rHDL-apoE3 promotes migration of human endothelial cells. Collectively, our findings support the heightened potential of rHDL-apoE3 to promote re-endothelialization and vascular endothelial repair following injury that may find clinical applications against ASCAD in the near future.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Valanti, Eftaxia-Konstantina
- Βαλαντή, Ευταξία-Κωνσταντίνα
Subjects
dc:subject × 20- Γονιδιωματική
- Bιολογικά φάρμακα
- Aθηροσκλήρωση
- Kαρδιαγγειακά νοσήματα
- ΗDL
- Aπολιποπρωτεΐνη E3
- Mετανάστευση ενδοθηλιακών κυττάρων
- Genomics
- Biological drugs
- Atherosclerosis
- Cardiovascular disease
- HDL
- Apolipoprotein E3
- Endothelial cell migration
- Βιολογία
- Φυσικές Επιστήμες
- Βιοχημεία και Μοριακή βιολογία
- Biological Sciences
- Natural Sciences
- Biochemistry and Molecular Biology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52538